Therapeutic efficacy of timentin and augmentin versus silvadene in burn wound infections.
Successful closure of thermal injuries, by either skin graft or delayed wound closure, largely depends on the ability to control the number of bacteria in the wound. The purpose of this study was to investigate the efficacy of two new antimicrobial agents, ticarcillin and clavulanate (Timentin) and amoxicillin and clavulanate (Augmentin), in the infected thermal injury. The therapeutic results were compared with the model treated with the standard topical silver sulfadiazine (Silvadene). Seventy-six Sprague-Dawley rats received a 20% full-thickness thermal injury and were then divided into six treatment groups. Three of the groups were inoculated topically with 10(8) Pseudomonas aeruginosa/ml, and three of the groups received topical inoculation of 10(8) Staphylococcus aureus/ml. The groups inoculated with P. aeruginosa received either intraperitoneal Timentin, topical Silvadene, or placebo treatment. The groups inoculated with S. aureus were treated with either enteral Augmentin, topical Silvadene, or placebo. The animals received 10 days of therapy and underwent tissue biopsies on alternate days. Statistical analysis showed that the level of bacteria in the wounds compared with the control group was significantly (p less than 0.05) decreased for both antibiotics tested as measured by quantitative wound biopsies. These studies demonstrate the efficacy of systemic Timentin and Augmentin in the infected thermal injury.
Heggers
J P
JP
Detroit Receiving Hospital-University Health Center, Michigan.
McHugh
T
T
Zoellner
S
S
Boertman
J A
JA
Niu
X T
XT
Robson
M C
MC
Velanovich
V
V
D000658:Amoxicillin / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D000818:Animals; D002056:Burns / Q000150:complications*; D002969:Clavulanic Acids / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D012837:Silver Sulfadiazine / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000627:therapeutic use*; D013982:Ticarcillin / Q000627:therapeutic use*; D014946:Wound Infection / Q000188:drug therapy*
D002969:Clavulanic Acids; D010406:Penicillins; D013411:Sulfadiazine; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin; D012837:Silver Sulfadiazine